Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2023-02-21 Declaration of Voting R…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states its purpose: 'NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF FEBRUARY 1, 2023' and cites compliance with the French 'Code de Commerce' and AMF regulations regarding the total number of shares outstanding and voting rights. This type of mandatory disclosure, detailing the capital structure and voting rights as of a specific date, is a routine regulatory filing. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is a specific, mandatory regulatory disclosure that doesn't fit the other precise categories (like DIRS, DVA, or SHA), the most appropriate classification is the general regulatory filing category, RNS, as it is a specific announcement required by the regulator (AMF).
2023-02-21 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 1ER FEVRIER 2023" and explicitly states it is published in accordance with French commercial code and AMF regulations regarding the number of shares and voting rights as of a specific date (February 1, 2023). This content directly relates to changes in the company's capital structure, specifically the total number of shares and voting rights, which is a form of capital/financing update or a specific notification related to share structure. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit for a formal announcement detailing the total number of shares and voting rights, as this directly impacts the capital structure. It is not a general earnings release (ER), a full annual report (10-K), or a director's dealing (DIRS).
2023-02-21 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-02-07 English
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a press release dated February 7, 2023, announcing that members of Innate Pharma's senior management are scheduled to participate in several upcoming investor conferences (SVB Securities, Citi's Oncology Summit, H.C. Wainwright Conference) throughout February 2023. This type of announcement, which details management's schedule for engaging with investors outside of formal earnings calls or regulatory filings, is best classified as general Investor Relations material. Since there is no specific category for 'Investor Conference Schedule Announcement,' and it is not a formal report (like 10-K, IR, ER), nor a specific transaction (DIV, DIRS, POS), it falls under the broad category of Investor Presentation (IP) if it were a presentation deck, or more generally, a communication aimed at investors. However, given the options, this is a direct communication about investor engagement activities. It is not a presentation (IP), nor a formal earnings release (ER). It is a general update about investor outreach. In the context of financial filings, announcements about management participation in investor conferences are often grouped with Investor Presentations (IP) or sometimes treated as Regulatory Filings (RNS) if they contain material non-public information, but here it is purely scheduling. Since it is a direct communication about investor engagement, and not a formal report or transaction, 'Investor Presentation' (IP) is the closest fit for investor-facing material that isn't a formal report or call transcript, although 'Regulatory Filings' (RNS) is a possible fallback. Given the content is purely about management's schedule for investor meetings, it aligns most closely with the intent of Investor Presentation (IP) materials, which are designed to communicate strategy and outlook to investors, even if this specific document is just the schedule for those meetings. I will classify it as IP as it is investor-focused communication.
2023-02-07 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "PROCHAINS RENDEZ-VOUS INVESTISSEURS D'INNATE PHARMA" (Upcoming Investor Meetings of Innate Pharma) and lists several upcoming investor conferences and summits where management members will be present (e.g., SVB Securities Global Biopharma Conference, Citi's 2023 Virtual Oncology Leadership Summit). This type of announcement, detailing management's schedule for engaging with investors, is a standard communication often released outside of formal earnings or annual reporting cycles. It does not fit the definitions for 10-K (Annual Report), ER (Earnings Release), IR (Interim Report), or DEF 14A (Remuneration). It is a general communication aimed at investors regarding corporate activities, which aligns best with a general Investor Relations announcement. Since there is no specific code for 'Investor Schedule Announcement', and it is not a presentation (IP) or a formal report announcement (RPA), it falls under the broad category of investor communication. Given the options, it is a general corporate update related to investor engagement, but it is not a formal regulatory filing like RNS, nor is it a presentation (IP). However, based on the content—announcing management participation in external investor events—it is a form of investor relations communication. If we must choose from the provided list, and recognizing that it is not a formal report or a specific transaction/change announcement, it is closest to a general investor communication. Since it is not a presentation (IP), the most appropriate general category for non-scheduled, non-financial-result-specific investor updates is often RNS (Regulatory Filings) if it must be classified, or potentially a very broad interpretation of Investor Presentation (IP) if the context implies a presentation will be given, but the text only lists attendance at conferences. Given the nature of announcing management roadshows/conference attendance, this is a common type of press release. It is not a proxy statement (PSI), director dealing (DIRS), or capital change (CAP). It is a general corporate update. I will classify this as RNS (Regulatory Filings) as the fallback for general corporate news releases that don't fit specific categories, although it strongly relates to investor relations activities.
2023-02-07 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-01-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.